Safety Outcomes
The frequency of adverse events related to the statin therapy was very
low in both groups, with myopathy occurring in around 0.8% and
increased ALT > three ULN in around 0.7% in both groups as
presented in Table 4 . Only three patients (0.3%) in the
atorvastatin 40mg group and no patient in the 80mg group discontinued
the statin therapy secondary to adverse events.